The $4.25 Million Cure Exists. Sixty-Four People Got It.

Sixty-four patients. In a full calendar year. Out of roughly 100,000 Americans with sickle cell disease.

That is the total number of people who received an infusion of Casgevy — the world's first CRISPR gene therapy, approved by the FDA in December 2023 to fanfare that made it sound like the end of genetic disease. Vertex Pharmaceuticals reported $116 million in Casgevy revenue for 2025. The math: roughly $1.8 million per patient treated.

One hundred and forty-seven more started the cell-collection process. Most haven't reached infusion. The pipeline is not a pipeline. It is a bottleneck with a waiting room.

The Price Table Nobody Wants to Print

Here is every gene therapy currently approved in the United States, listed by what it actually costs.

Therapy	Disease	Price	Patients Treated (est.)	Status
Lenmeldy	Metachromatic leukodystrophy	$4.25M	Handful	Approved Mar 2024
Elevidys	Duchenne muscular dystrophy	$3.2M	~1,000	Sarepta ramping
Skysona	Cerebral adrenoleukodystrophy	$3.0M	<50	⚠️ FDA investigating blood cancer risk
Roctavian	Hemophilia A	$2.9M	~100	⚠️ BioMarin seeking to divest
Zynteglo	Beta-thalassemia	$2.8M	<100	Genetix Bio (ex-Bluebird)
Hemgenix	Hemophilia B	$3.5M	<50	CSL Behring — slow uptake
Casgevy	Sickle cell / beta-thal	$2.2M	64 (2025)	Vertex — $116M revenue
Lyfgenia	Sickle cell disease	$3.1M	~100	Genetix Bio

Eight approved gene therapies. Combined, they've probably treated fewer than 2,000 people worldwide. The diseases they target collectively affect millions.

The Graveyard

Bluebird Bio was supposed to be the proof of concept. Founded in 1992, three FDA-approved gene therapies by 2023, pioneer of the entire field. It is now called Genetix Biotherapeutics and is owned by private equity.

The collapse happened in stages. First, Bluebird pulled out of Europe entirely — couldn't negotiate reimbursement for Zynteglo or Skysona with any national payer. Then layoffs. Twenty-five percent of the workforce in one round. Then the private equity acquisition in February 2025. The name change followed — a rebrand to Genetix Biotherapeutics, as if a different name could solve the math.

The math is this: manufacturing a single-patient batch of a lentiviral gene therapy costs between $500,000 and $1 million. That is the cost of goods. Not the price. The cost.

BioMarin's Roctavian tells the same story from the other side. List price: $2.9 million. Third-quarter 2025 sales: $3 million. That is approximately one patient per quarter. The company put the manufacturing plant into "idle state" in August 2024, cut the commercial footprint to three countries, and in October 2025 announced it was seeking to divest entirely. Analysts called the announcement "a bit anti-climactic at this point."

The Conditioning Problem

Pricing is the headline. But it is not the only wall.

Both Casgevy and Lyfgenia require myeloablative conditioning with busulfan chemotherapy before infusion. The treatment destroys the patient's existing bone marrow to make room for the corrected cells. It also destroys fertility in most cases. Courtney Rice of Acadia Strategy Partners described it plainly: "That conditioning regimen is gnarly at best."

For sickle cell patients — overwhelmingly young, overwhelmingly Black, often employed and managing their disease — the calculation is not just financial. It is months of hospitalization, guaranteed infertility, and a recovery period that looks a lot like surviving cancer treatment. Cantor Fitzgerald noted: "Sterility is a hot button issue in the SCD community." Younger patients cannot always bank sperm or eggs before treatment.

Victoria Gray, the first human treated with Casgevy, said the answer is in vivo gene therapy — editing genes inside the body without extracting cells, without chemotherapy, without months in a hospital bed. Tessera Therapeutics secured $50 million from the Bill & Melinda Gates Foundation in December 2024 to build exactly that.

The Manufacturing Trap

Gene therapy is bespoke. A patient's cells are extracted, shipped to a cleanroom, genetically modified, expanded, quality-tested, and shipped back. The FDA's new Advanced Manufacturing Technologies designation exists because the agency itself recognizes the manufacturing process is broken — companies enter the market with "hands-on, less automated" processes that buckle under commercial demand.

Anna McMahon of Cellares — a company building automated cell therapy factories — put it this way: relying on manual handling and paper records causes production to "buckle" under pressure. Supply delays. Missed treatment slots. Growing waitlists.

Dendreon went bankrupt in 2014 over this. Bluebird went bankrupt in 2025 over this. The pattern is consistent: brilliant science, approved product, manufacturing crisis, commercial failure.

The ICER Question

ICER — the Institute for Clinical and Economic Review — evaluated Lenmeldy and determined a cost-effective price ceiling of roughly $3.94 million based on lifetime benefits. Kyowa Kirin priced it at $4.25 million — 8% above ICER's ceiling. For a disease where half of late-infantile patients die within five years without treatment.

This is the fundamental tension. A one-time gene therapy that prevents decades of disease management, hospitalizations, and early death may genuinely be worth millions when measured against the alternative. The problem is not that the price is irrational. The problem is that no payment system on Earth is designed to write a single check for $4.25 million.

Outcome-based agreements are the industry's current answer. Pay in installments. Pay only if the therapy works after one year. Pay only if the patient survives to five years. It is the pharmaceutical equivalent of a mortgage — except the house is inside a child's bone marrow.

What Works, and What Doesn't

Sarepta's Elevidys is the closest thing to a commercial success in the space. Roughly 1,000 patients treated, addressing ~90% of the U.S. DMD population. Revenue is climbing. But Duchenne is a disease of children — desperate parents, aggressive advocacy groups, and a patient population small enough that a $3.2 million price point can work when insurers are cornered.

Everything else is stalling. Hemgenix (hemophilia B, $3.5 million) has been outcompeted by prophylactic factor replacement that patients already know and trust. Roctavian (hemophilia A, $2.9 million) lost to Roche's Hemlibra and Sanofi's Altuviiio. Casgevy and Lyfgenia are drowning in conditioning reluctance.

The pattern: gene therapy wins the science, wins the approval, and loses the market to treatments that are worse but easier.

The Next Five Years

Fifteen additional gene and cell therapies may be submitted to the FDA in 2025 alone. The pipeline is deep. The science is real. CRISPR editing efficiency has improved by orders of magnitude since the first ex vivo protocols.

None of that matters if the delivery model doesn't change. In vivo editing — no cell extraction, no conditioning, no cleanroom — is the path. Tessera, Verve Therapeutics (cardiovascular gene editing), and Prime Medicine (prime editing platform) are all pursuing it. If any of them work, gene therapy stops being a million-dollar bespoke procedure and starts being an injection.

Until then, the cures exist. They sit in freezers. And the people who need them sit in waiting rooms, doing the math on whether a cure is worth the chemo, the infertility, the months, and the price of a house they'll never own.